The revised amount is then reviewed against the updated medical details, available cover and applicable policy terms before any additional cashless approval is provided.

When Does a Cashless Enhancement Become Necessary?

The amount approved when a patient is admitted is based on the treatment information available at that point. Medical care can change after admission. The doctor may recommend another procedure, additional investigations or a longer period of hospital care.

In such situations, the earlier approved amount may no longer be sufficient for the expected treatment. The hospital insurance desk can then approach the insurer for an enhancement of the cashless limit. The mediclaim policy premium paid for the cover does not determine whether this additional amount will be approved.

Who Sends the Request for a Higher Cashless Amount?

In a cashless hospitalisation, the network hospital generally coordinates with the insurer or TPA. If the expected cost rises, its insurance desk submits the revised request on behalf of the patient.

The hospital may provide:

• The revised treatment plan
• Updated medical notes
• Details of additional procedures or investigations
• A revised estimate of hospital expenses
• Other medical information requested for assessment

The patient normally does not need to file a completely new cashless claim simply because the expected cost has increased.

Does the Insurer Have to Approve the Entire Increase?

Not necessarily. The insurer reviews the reason for the increased amount and checks how much of it can be considered under the policy. The outcome may therefore differ depending on the claim.

The insurer may approve the requested enhancement, approve a different amount or seek further information before making a decision. This review is important because the revised hospital estimate can contain expenses beyond those considered in the initial cashless request.

What Can Affect the Revised Approval?

A change in treatment cost is only one part of the assessment. The insurer also considers the policy conditions that apply to the hospitalisation.

These may include:

• The available sum insured
• Applicable room eligibility
• Co-payment requirements
• Deductibles under the policy
• Sub-limits applicable to certain expenses
• Whether the additional treatment relates to the covered hospitalisation

This means a higher treatment estimate does not automatically translate into an equal increase in cashless approval.

What if the Enhancement Is Only Partly Approved?

A partial enhancement means the insurer has approved only part of the additional amount requested by the hospital. The hospital insurance desk can explain the revised approval and whether any further documents are needed for assessment.

The patient or family can also contact the insurer if the approved amount is unclear. While the mediclaim premium is important when choosing a policy, it does not decide how much of an enhancement request will be approved. That depends on the treatment details, available cover and applicable policy terms.

Can Another Enhancement Be Requested Later?

Further revision may be required if the treatment changes again during the same hospital stay. For example, the doctor may decide that additional hospital care is medically required after the first enhancement has already been processed.

In such a situation, the hospital can communicate the updated requirement to the insurer. Each additional request is assessed using the latest medical information and the applicable policy terms.

What Should You Do When the Expected Cost Goes Up?

If the hospital informs you that the treatment estimate has increased, first check whether its insurance desk has requested an enhancement.

You can also:

• Ask for the current cashless approval status.
• Check whether additional documents are required.
• Confirm how much enhancement the hospital has requested.
• Review any revised authorisation communicated by the insurer.
• Ask the hospital to explain amounts that may need to be paid directly.

Staying informed during the hospital stay can reduce confusion when the final discharge process begins.

Final Thoughts

Cashless approval can be revised when treatment costs increase during hospitalisation. The network hospital usually requests an enhancement by sending updated treatment and expense details to the insurer or TPA.

The insurer then assesses whether the additional amount can be authorised under the policy. Since approval depends on medical information, available cover and policy conditions, the revised cashless amount may not always match the hospital’s increased estimate.

The post Can Cashless Approval Be Revised if the Treatment Cost Increases? appeared first on The American Reporter.

Parents often catch their children’s vision problems in one of a couple of scenarios. One telltale sign of a vision problem is poor performance in school. If a student is having difficulty reading or writing, focusing on tasks at school, and sometimes acting out because they can’t see properly, it could be a sign that something about their vision needs attention. Alternatively, some parents discover vision difficulties when a pediatrician conducts a vision screening at their annual check-up or physical. 

However, parents don’t have to wait for an annual exam or until vision problems start impacting their children’s behavior in school. Sally Murray, a certified orthoptist and Director of Promotions and Development at the American Association of Certified Orthoptists (AACO), explains that there are several ways in which an eye problem can manifest in children. 

Vision problems that could indicate your child needs eye care

One of the most obvious indicators that a child might have an eye problem is constant, visible eye crossing. Intermittent eye crossing is normal in children in early infancy, up until around the time they are 4 months old, but after that, even intermittent crossing may indicate a deeper problem. That said, constant crossing of the eyes is never normal.

“You can often confirm an eye crossing by using a flash on your camera phone,” says Murray. “If the light reflections are symmetrical, the eye turn is unlikely to be constantly present.”

Another common physical sign of a potential eye coordination problem is abnormal head posture. If a child keeps their head turned or tilted, it may be because they see better in that gaze, which could imply a misalignment in the opposite gaze. For example, if a child has strabismus, tilting their head could help them line up images and help them compensate for the eye misalignment, or if they have nystagmus, tilting or turning could reduce shaking and cause vision to become clearer.

Eye coordination problems can also manifest in children’s behavior. For example, children with poor vision might seem extremely introverted or uninterested in their surroundings due to their inability to see things clearly, which they assume is normal. Young children may lack the vocabulary to describe the vision difficulties they are experiencing; thus, this type of phenomenon generally has to be observed by a parent or teacher rather than described by the child themselves.

Children experiencing eye coordination problems may also have a specific reaction to external stimuli. For example, infants with an eye coordination problem may cry when only one eye is covered.

“Many children don’t like their face being covered and will scream when any eye is covered,” explains Murray. “However, if they only scream when one eye is covered, and it’s always the same eye they react to, it could indicate a potential problem.”

In older children, this frustration might manifest itself in other ways. For example, a child closing one eye in bright sunlight could indicate potential strabismus, as closing one eye can prevent visual discomfort when the control of their eye misalignment is challenged. While occasional squinting of both eyes together is often normal, squinting only one eye can be a sign that testing is needed, especially if it is always the same eye.

When one of these indicators of a potential vision misalignment is discovered, a patient will often be referred by their pediatrician to a pediatric ophthalmologist and orthoptist for more advanced testing and treatment. As highly specialized eye care professionals, orthoptists are specially trained to diagnose and manage binocular vision disorders. They will work with the doctor to find a nonsurgical or surgical treatment that can help improve their long-term vision.

Why vision screenings with an orthoptist are so important for pediatric eye health

It is important to catch and treat eye misalignment issues in childhood because early intervention can prevent children from developing poor eyesight in one eye (amblyopia) that lasts their entire lifetime. The vision system is still developing in childhood, so early treatment such as patching will improve vision before the age of approximately 8 years. 

If eye misalignment (strabismus) persists after amblyopia is treated, eye muscle surgery will align the eyes.

“If your child is experiencing one of these signs of a vision misalignment or poor vision, contact your pediatrician about a referral to an ophthalmologist and orthoptist today,” concludes Murray. “A certified orthoptist can evaluate your child’s vision and work in conjunction with an ophthalmologist to ensure that your children’s eye health is on track for them to grow up with healthy vision in adulthood.”

The post The Hidden Signs Your Child May Have an Eye Problem: Why Pediatric Eye Care and Children’s Eye Health Are So Important appeared first on The American Reporter.

However, for Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic condition, the primary patient-derived cells are fragile, slow-growing, and finite. This biological scarcity has restricted the use of Hi-C technology, the gold standard for 3D genome mapping, creating a knowledge gap regarding how the nuclear architecture is associated with this disease, specifically in the fat cell development process.

Recognizing this bottleneck, molecular biologist Nishita Gogia re-engineered the technology to suit the limited, scarce cell material available. Her work provides a methodological bridge between the limitations of rare disease samples and the data-intensive demands of modern genomics.

The Data Scarcity Problem in Rare Disease

Progeria is a premature/accelerated aging syndrome caused by a single point mutation in the LMNA gene, which produces the abnormal, truncated protein progerin. Progerin destabilizes the nuclear envelope, misshaping the nucleus and disorganizing the chromatin inside the nucleus.

Researchers used High-throughput Chromosome Conformation Capture (Hi-C) to map the genome’s 3D spatial contacts. While the lab had expertise in Hi-C, applying it to primary patient-derived cells was new. Standard Hi-C needs five to ten million cells, typically from cell lines. However, progeria fibroblasts are “primary” cells with a short lifespan. Expanding them for standard Hi-C risks of losing the culture or cell death.

Engineering the Low-Input Workflow

Gogia engineered a low-input genomic workflow. This required a ground-up recalibration of the standard sequencing protocol. Her initial task was foundational: architecting optimized 2D culture protocols that allowed these delicate primary fibroblasts to grow efficiently for significantly longer periods than previously achievable.

“Working with primary patient-derived material is fundamentally different from working with established cell lines,” Gogia explains. “Everything is harder, the yields are lower, and there is almost zero margin for error. If the culture conditions aren’t perfect, you lose months of work before the experiment even begins.”

For weeks, Gogia tested varying media conditions, passage timings, and seeding densities. The goal was to keep the cells viable long enough to reach a critical mass, even if that mass was far below the industry standard for genomics. Once the culture protocols were stabilized, she turned her attention to the Hi-C workflow itself.

The standard protocol involves several high-loss steps: cell lysis, restricting digestion of the DNA, biotin labeling, and ligation. In a sample of five million cells, losing 20% of the material at each step is acceptable. In a sample of 50,000 cells, it is catastrophic. Gogia had to rethink the protocol at every stage to minimize loss and maximize “signal-to-noise” ratio.

Navigating Technical Obstacles

Gogia overcame significant technical hurdles to successfully apply Hi-C to low-input samples, particularly primary patient-derived cells. The first step of calibration was to isolate the nucleus from the cells, which required calibration, as it would significantly reduce the debris carried over from the whole cell mass, further standardizing the cross-linking conditions and tweaking reaction times across the Hi-C protocol led to a successful protocol execution of these primary cells. The final challenge was library preparation. Gogia noted the difficulty is preserving the genome’s architectural signal over technical noise, especially with minimal material, where errors are magnified. This landmark achievement allows researchers to study 3D genome organization in a disease-relevant context without cell immortalization, which can mask aging signatures.

Impact on the Regulatory and Scientific Landscape

The broader significance of this work is tied to the evolving landscape of genomic medicine, specifically as regulatory bodies and funding agencies like the National Institutes of Health (NIH) emphasize the transition toward “disease-relevant” models. While immortalized cell lines have served as the backbone of research for decades, they are often poor proxies for the actual physiological state of a patient. By bridging this gap, Gogia’s innovation aligns with a global shift toward precision medicine, where the focus is on the individual rather than the average.

Crucially, the low-input Hi-C protocol engineered by Gogia is not a localized success limited to a single laboratory; it is a replicable methodological blueprint with global implications. By providing a validated pathway to study the 3D genome in primary patient cells, she has created a toolset that can be exported to any research context where patient material is scarce. This standardized approach can now be utilized for other laminopathy models affecting cardiac and muscular health, rather than being restricted solely to HGPS. .

Within the organization, the impact of this new standard was immediate. The low-input workflow became a foundational tool that transformed the lab’s strategic capabilities, allowing the team to move to investigate how a specific patient’s mutation physically alters their genomic layout. 

“When you can finally see the physical layout of the genome in a patient-derived cell, you’re not just looking at a list of genetic instructions,” Gogia reflects. “You’re seeing the structural foundation of life. If the foundation is misaligned, every downstream process, from how the cell reads its own genes to how it repairs its own damage, is compromised. By standardizing the way we see these failures, we aren’t just solving a problem for one lab; we’re giving the global research community a way to finally see the core of these diseases in high resolution.”

A Legacy of Methodological Innovation

Nishita Gogia’s role in this project was far more than that of a traditional graduate researcher. In an environment where most peers were executing established protocols, she was an innovator of the protocols themselves. Her ability to operate at the intersection of three challenging domains, primary cell biology, high-resolution genomics, and rare disease pathology, distinguishes her work from standard academic contributions.

Key outcomes include a stabilized research pipeline, a validated low-input technology platform, and new insights into the spatial biology of aging specifically in the context of fat cell formation. This research has been presented at prestigious venues like Cold Spring Harbor Laboratory and the Progeria Research Foundation, where the utility of her low-input approach was recognized.

Looking Forward: The Future of Genomic Mapping

As the scientific community moves toward a more nuanced understanding of “epigenomics”, the study of how the genome is regulated beyond just the DNA sequence, spatial organization has become a central pillar of research. The tools developed by Gogia ensure that researchers studying the rarest of diseases are not left behind in this genomic revolution.

The “Architecture of Aging” is no longer a metaphorical concept; thanks to the technical ingenuity of researchers like Gogia, it is a mapped reality. By engineering a solution to a physical limitation, she has ensured that the most vulnerable cells can finally tell their story in high resolution.

“The goal isn’t just to produce a single map,” Gogia says. “It’s to build a set of tools that can handle the complexity of human biology as it actually exists, scarce, fragile, and difficult to capture. If we can map the most challenging cells in the world, we can map anything.”

The institution continues to build on this foundation, utilizing the workflows Gogia established to investigate potential therapeutic targets that could one day “re-stabilize” the warped genomes of progeria patients. In the high-stakes world of rare disease research, where every cell counts, Gogia’s contributions have provided the field with a much-needed margin for success.

The post The Architecture of Premature/Accelerated Aging:  High-Resolution Genomic Maps for Rare Disease Research appeared first on The American Reporter.

Emma Wellness, a natural health brand curated by homesteader and healthy-living expert Emma Magnolia, is part of this shift toward supporting healthy gut function. The brand’s website offers a collection of home therapies designed to support digestion, the gut microbiome, mineral balance, and overall health through gentle, at-home routines. 

Emma Wellness’s approach to supporting gut function reflects a simple yet trustworthy ideal: digestive system support does not always have to begin in a clinic or rely on aggressive intervention to be complete. Instead, carefully chosen home therapies that fit into daily lives can support gut function using the body’s own rhythm.

In recent years, home therapies have attracted the attention of people seeking practical, non-invasive ways to heal their gut and naturally quell digestive discomfort. Emma Magnolia has stepped forward with Emma Wellness to help those people access the best holistic home therapy products available.

A wellness brand built around the home

For every product that Emma features on her brand’s website, the connection to home is clear. Emma Wellness is more than just a supplement shop; it also offers natural health products, books, and handcrafted remedies curated by Emma herself. 

A healthy gut microbiome and supporting your gut are part of a broader lifestyle model that emphasizes consistency, accessibility, and self-care. 

“Gut function is not only about digestion,” explains Emma. “It can affect energy, mood, appetite, comfort, and long-term health.” 

When people eat a lot of processed foods, eat quickly, or otherwise fail to treat their digestive tract gently, it can lead to bloating, constipation, diarrhea, and other gastrointestinal upsets. The collection at Emma Wellness is aimed at addressing everyday digestive issues, with products that support gut comfort and nutrient absorption. 

Emma Wellness’s products are designed to fit into family routines and feel manageable rather than overwhelming. The approach meets people where they are, giving them easy daily habits they can incorporate into the regular ebb and flow of their routine.

The Emma Wellness collection

The Digestive Help + Minerals collection from Emma Wellness focuses on gentle digestive support with mineral balance and repairing the gut lining, with the site noting benefits tied to gut comfort, nutrient absorption, and vitality. Within the brand’s broader digestive lineup, it highlights items including Gut Repair Powder and activated charcoal capsules, giving consumers a small set of targeted options rather than a confusing aisle of wellness products at their local drugstore.

Emma Wellness’s Gut Repair Powder is one product that fits into a restorative routine focused on digestive comfort and nourishment. Activated charcoal capsules are marketed for gentle detox and waste elimination, showing the brand’s emphasis on practical, home-based support tools. 

“It’s not about quick fixes, but about building a supportive environment in the home that helps create a supportive environment for digestion,” says Emma.

Emma’s platform encourages people to make home therapies part of a broader health pattern that includes hydration, time outside, a clean diet, good eating habits (including fermented foods), and rest. The products serve as an anchor for a healthy lifestyle that respects how sensitive digestion can be. When people learn to support their gut gently and consistently, they will soon notice changes in their day-to-day comfort levels.

Digestive health is tied to the home environment

It may seem that digestion issues and the home environment are unrelated, but digestive function is closely tied to the home environment, especially the kitchen. Factors such as hydration, excluding drinking with one’s meal (which is detrimental), diet, how fast or slow we eat, and stress can negatively impact our gut bacteria balance and gut function. Home therapies matter because they are adaptable, easy to personalize, and often considered less intimidating than more intensive, clinical approaches. As a result, they can help people create a healthy structure that their bodies have been missing.

There are also notable psychological benefits to home-based therapies for gut health. When people can participate in their own wellness routines, adjusting their approach day to day until they land on something that works for them, they often come away feeling more in control and more aware of what their bodies need. Because digestion can be negatively impacted by stress and inconsistency, this brain-gut connection matters even more.

The focus on minerals in the Emma Wellness collection also reflects the connection between nutrient balance and overall gut function, especially for people who regularly feel depleted or run down. Products such as the Baja Gold Liquid Ocean Minerals and the Mineral Sea Salt help replenish electrolytes, boost magnesium, and provide a jump start to vitality through mineral nutrients. 

“Digestive care is something that belongs in everyday life,” says Emma. “It’s not just a response to a problem, but a holistic lifestyle approach.”

Old wisdom addressing modern issues with poor gut health

Much of what Emma shares through Emma Wellness is health wisdom passed down from her family. Her website provides timeless advice that reflects how people have turned to the home first for relief, comfort, and restoration. 

Emma Magnolia has curated and packaged these remedies and presented them with resources and education to help consumers tap into the body’s ability to heal itself. In a market full of health-aligned promises, Emma Wellness offers tools for the home that support the body and gut health every day.

The post Ways to Improve Gut Health Naturally: How Home Therapies Support Digestive Function appeared first on The American Reporter.

The terms sound similar, yet they serve different purposes. Understanding the distinction helps Indian travellers assess whether a policy suits their destination and trip.

What Medical Evacuation Cover Means

Medical evacuation is the movement of an insured traveller to a place where suitable medical care can be provided. It may become relevant when the nearest facility cannot offer the treatment required.

The transfer could involve ground transport, an air ambulance or another medically appropriate arrangement. The assistance provider usually assesses medical necessity and coordinates the transfer. Travellers should not assume every move between hospitals will qualify.

When purchasing travel insurance online, check whether evacuation costs form part of the medical benefit or carry a separate limit.

What Medical Repatriation Cover Means

Medical repatriation generally refers to returning an insured traveller to India after treatment abroad when the return is considered medically necessary and safe. It is different from ending a trip early for personal convenience.

A treating doctor, the insurer’s medical team and the assistance provider may help decide whether the traveller can return. Depending on the policy, arrangements may include:

• A medically suitable commercial flight
• Special seating or additional space
• An accompanying medical professional
• Transport between the hospital and airport
• Continued care during the journey

Approval should usually be obtained before arrangements are made.

How Evacuation And Repatriation Differ

Both benefits concern medical transport, but their purpose differs. Reading them separately can prevent confusion during an emergency.

Medical evacuation usually moves the traveller to a suitable treatment facility, which may be in the same country or another nearby location. Medical repatriation brings the traveller back to the home country once the journey is medically appropriate.

Some policies refer separately to repatriation of mortal remains. This concerns transporting a deceased insured person to India and is not the same as medical repatriation.

Why The Cover Matters Overseas

Suitable medical care may not be available in every location. A traveller could be far from an appropriate hospital, or a local facility may recommend treatment elsewhere. Such transport can involve medical planning, specialist equipment and coordination across borders.

For Indian travellers applying for a European visa, travel insurance for a Schengen visa should be reviewed for the required medical and repatriation protection. The policy must also remain valid for the relevant destination and travel period.

The benefit does not make every expense payable. Eligibility depends on medical necessity, covered circumstances and policy conditions.

When Medical Transport May Be Considered

The need for evacuation or repatriation is generally determined by the traveller’s condition and the care available locally. It is not based only on discomfort or preference.

Situations that may lead to an assessment include:

• A serious accidental injury
• A sudden illness requiring advanced treatment
• Lack of suitable medical facilities nearby
• A doctor recommending transfer for continued care
• A condition that prevents ordinary travel

The insurer may request reports from the treating hospital before approving transport. Travellers or companions should contact the emergency assistance team as early as possible.

What The Benefit May Cover

The expenses considered depend on the policy and the approved transport plan. This cover is usually intended for necessary medical movement rather than ordinary changes to travel arrangements.

Eligible costs may include:

• Ambulance transport to a suitable facility
• Medical support required during transfer
• Air transportation arranged for medical reasons
• An escort where medically required
• Coordination by an emergency assistance provider
• Approved transport for returning to India

Hotel stays, upgraded tickets chosen for comfort, unapproved transfers and unrelated travel costs may not be included. The policy schedule and wording should be read together.

Why Prior Approval Matters

Medical evacuation is rarely handled like a routine reimbursement claim. The assistance team may need to speak with doctors, identify an appropriate facility and arrange transport suited to the traveller’s condition.

Independent arrangements can create difficulties. The transport may not be medically necessary, the cost may exceed policy limits, or important documents may be missing.

During an emergency, the traveller or companion should provide:

• Policy and contact details
• Hospital and location information
• Available medical reports
• The treating doctor’s details
• A clear account of the situation

Following the assistance team’s instructions can make coordination easier.

Exclusions And Conditions To Check

Evacuation and repatriation benefits are subject to exclusions. These vary between policies, so relying on assumptions can lead to misunderstandings.

Travellers should review terms concerning pre-existing illnesses, undisclosed medical information, high-risk activities, self-inflicted injury, intoxication, unlawful conduct and travel against medical advice. Non-medical evacuation from conflict areas may also be treated differently.

Check deductibles, benefit limits, geographical validity and whether the insurer must authorise the service. Accurate disclosure at the proposal stage is equally important.

Final Thoughts

Medical evacuation moves a traveller to appropriate care, while medical repatriation supports an approved return to India after a serious medical event. Both may matter when treatment is unavailable nearby, or ordinary travel is medically unsuitable.

Before departure, travellers should carefully read the definitions, limits, exclusions and authorisation process. Keeping policy details readily accessible and contacting the assistance team promptly can support better coordination during a medical emergency.

The post What is Medical Evacuation and Repatriation Cover in Travel Insurance? appeared first on The American Reporter.

In “Health Care: Compassion In Action”, author Gregory Gallivan argues that today’s healthcare model treats doctors and patients as cogs in a sprawling industry machine. Not only is his solution to the broken relationship obtainable, but his ground-breaking book also lays out a plan that can be approved in just 24 hours and implemented in under two years.

Why Greg Gallivan set out to fix the American health care system

Gallivan’s motivation is personal. He grew up in a household of medical professionals and watched his parents try to deliver a high level of care despite mounting challenges. 

Gallivan’s father, a respected thoracic surgeon, allowed his son to accompany him on his rounds. That uniquely hands-on apprenticeship ultimately led Gallivan to pursue studies in the medical field, until he received an unexpected warning from the man he idolized.

“My father looked me in the eye and told me to stop studying medicine,” recalls Gallivan. “He had devoted his life to assisting others, but he eventually reached the point where he had to warn me that the system had become too broken to recommend as a career to the next generation.”

But the spark that ignited the plan came from dropping a close friend’s three-year-old son off at daycare. As Gallivan listened to the little boy chatter about his dreams, the innocent enthusiasm hit him hard. He imagined the world that child would grow into, and the reality the child’s mother was already facing as a registered nurse.

Gallivan became even more convinced of the problem from an Uber ride when he drove the CEO of a major healthcare company to Logan Airport. During the ride, he was stunned to learn that there was no reasonable plan in the works. The Affordable Care Act’s federal subsidies ended at the start of 2026.

Months later, another high-ranking executive rode with Gallivan and told him the same. Between those two rides, however, he developed a plan.

He laid out the details and honestly asked that second executive whether the plan would work. In answer, she leaned into his passenger-side window in the rain outside her company’s headquarters and said, “You have to write this. You need to write this.”

Reimagining healthcare with an à la carte insurance model

Gallivan’s first major reform is centered on consumer choice. He proposes an à la carte insurance model designed to create modifiable family programs because different people, whether a newly married couple, a single parent with two kids, or seniors, all need vastly different coverage. When they are forced into a menu of rigid plans, the insurance never fits. 

“Make coverage adaptable, and the doctor and patient will once again be the center of healthcare,” Gallivan argues. “They will make health decisions based on their conversations in the exam room, not based on forms written by insurance companies.” 

Saving America’s healthcare system with education reform

Even the best insurance design will not matter if there are not enough people to deliver care. Gallivan believes that solving this requires an education system that actively encourages the nation’s brightest and most altruistic children to pursue healthcare careers. 

Notably, Gallivan wants to start early with a 4th-grade initiative program because by the time many students reach high school, the pipeline determining who may be able to become a doctor or nurse has already narrowed. However, this early initiative creates equality for all children before financial barriers or lack of guidance shut doors.

Increasing middle-class spending has the power to revitalize health care

Gallivan next focuses on the financial foundation beneath the entire system. His plan to increase the dollar’s purchasing power will ultimately reduce the number of people relying on state and federal aid programs.

When people can afford more, they can participate more fully in the healthcare system by getting preventive care to address issues earlier, filling prescriptions without worrying about their costs, and avoiding many of the expensive emergencies that overwhelm hospitals and patient budgets today. Plus, as purchasing power increases and fewer people require assistance, tax revenue will rise for states and the federal government, creating even more capacity to strengthen core services.

Gallivan firmly believes America can turn its struggling healthcare system around in just two years. His book’s solution is surprisingly practical, but the explanation takes readers on an engaging journey through several decades of crucial history and into a hopeful future.

“A promising future is just ahead,” Gallivan concludes. “We have everything in place to make this dream a reality. It is time to replace all the theory with common sense actions that work for everyone.”

The post Reimagining Healthcare: Gregory Gallivan’s Case for Consumer Choice and Systemic Reform appeared first on The American Reporter.

The cost and speed of DNA sequencing have fallen dramatically, making genomic information increasingly practical for clinical use. At the same time, biomarkers and wearable devices are creating a much more continuous picture of how an individual’s health changes.

The bigger opportunity is what happens when these streams come together. Genomics can indicate what someone may be predisposed to; biomarkers can show what is happening now; continuous tracking can reveal how the body responds over time.

That changes the purpose of personalized medicine. It is not simply about finding a more sophisticated diagnosis after someone becomes sick. It is about building enough individual context to identify meaningful risk earlier and make treatment more precise.

The real shift, therefore, is from treating the average patient to understanding the individual patient. 

The 4D Health Stack

The real power of personalized medicine will not come from one DNA test. It will come from stacking four layers of information.

1. Static Baseline- Genomics: DNA provides the inherited blueprint: what a person may be predisposed to.
2. Dynamic Reality- Biomarkers: Measures such as ApoB, hs-CRP and blood glucose show what is happening biologically now.
3. Continuous Context- Wearables: Heart rate, sleep, activity and continuous glucose data can reveal how the body responds to everyday behaviour over time.
4. Clinical Decision Engine- AI + Physician: The final layer turns these signals into something useful: a doctor can combine the data with medical history and decide what actually warrants intervention.

This framework matters because more data is not the same as better medicine. The value comes from connecting different types of information. A genetic predisposition might look concerning in isolation but become far more or less relevant when viewed alongside current biomarkers and long-term trends.

The future of personalized medicine, therefore, is not a bigger genetic report. It is a connected health profile that turns biological complexity into a clinical decision.

When Your Genes Change The Prescription

Personalized medicine becomes much more tangible when it reaches the prescription pad. Pharmacogenomics can show that two patients taking the same drug may process it differently because of genetic variation.

Take CYP2C19 and clopidogrel, an antiplatelet drug used to reduce the risk of cardiovascular events. CYP2C19 helps convert clopidogrel into its active form. People with reduced-function variants can produce less active drug, potentially reducing platelet inhibition and increasing cardiovascular risk. CPIC guidelines therefore use CYP2C19 genotype to help guide antiplatelet therapy in relevant patients.

The same principle applies to CYP2D6 and CYP2C19 for several commonly used antidepressants. Genetic differences can influence how these medicines are metabolized, affecting their potential efficacy, tolerability and dosing considerations.

This is where personalized medicine becomes genuinely practical. The question is no longer simply which drug treats the disease, but which drug is more likely to work for this particular patient.

That could reduce some of the trial-and-error built into prescribing but only where the genetic evidence is strong enough to support a clinical decision. 

From Single Genes To Thousands Of Genetic Signals

Most major diseases are not controlled by one gene. Conditions such as coronary artery disease and Type 2 diabetes are influenced by hundreds or thousands of genetic variants, each contributing a small amount to overall risk.

This is where polygenic risk scores (PRS) become interesting. Instead of looking for one “disease gene,” a PRS combines the effects of many genetic variants to estimate an individual’s inherited susceptibility to a complex condition.

The potential is significant. Someone may have a high inherited risk for coronary artery disease despite having no symptoms today. That information could potentially support earlier screening or more focused prevention, particularly when combined with conventional factors such as cholesterol, blood pressure and family history.

But PRS should not be treated as a prediction of destiny. Its usefulness can vary across populations because many genetic studies have historically relied heavily on people of European ancestry. A score that performs well in one population may not perform equally well in another.

That limitation matters. Personalized medicine cannot truly be personalized if the underlying data does not represent the people it is being used on.

The opportunity is therefore substantial but so is the responsibility to make genomic prediction clinically validated, diverse and actionable. 

The Prevention Paradox: Who Pays For A Healthier Future?

Personalized medicine could make prevention more valuable, but healthcare economics may not always reward it.

Suppose a genomic test identifies elevated cardiovascular risk today and leads to years of earlier monitoring and intervention. The savings from avoiding a major cardiovascular event may occur far into the future. Yet the insurer paying for the test today may not be the same insurer covering that patient years later.

This creates a reimbursement paradox: the organisation funding prevention bears the immediate cost, while another payer or the healthcare system as a whole may capture much of the future benefit.

The problem becomes even harder when the value of a test is measured against conventional healthcare budgets. A genomic panel can produce useful information without immediately producing a billable treatment. That makes it harder to fit into a healthcare model historically built around diagnosing and treating existing disease.

I see this as one of the biggest barriers to personalized medicine at scale. The technology may become affordable before the economics catch up.

For genomic prevention to move beyond premium healthcare, insurers and health systems will need to evaluate long-term avoided costs and improved outcomes, not simply whether a test creates an immediate medical intervention.

Otherwise, healthcare could remain financially structured to reward treating disease rather than preventing it. 

The N-of-1 Trial: When the Patient Becomes the Experiment

Personalized medicine could eventually change more than treatment, it could change how we generate evidence.

Traditional clinical trials are designed to discover what works for large populations. That is essential for proving whether a treatment is safe and effective, but it inevitably produces averages. Personalized medicine introduces another possibility: the N-of-1 trial, where an individual’s response to an intervention is tracked systematically over time.

Imagine a patient with a particular genetic profile, metabolic pattern and set of biomarkers. Instead of relying only on population averages, clinicians could track how that specific patient responds to a dietary intervention, medication or other clinically appropriate change, using repeated measurements to assess the outcome.

This does not replace large clinical trials. Population-level evidence remains the foundation of safe medicine. But N-of-1 approaches could add another layer of evidence: what works for this patient, under these conditions?

That is a profound shift. Medicine has historically asked, “Does this treatment work on average?” Personalized healthcare increasingly asks a second question: “How does this individual respond?”

The future may therefore combine both forms of evidence, large trials to establish what generally works and individual-level data to refine what works best for a particular patient. 

The Downside Of Too Much Information

The biggest mistake in personalized medicine would be assuming that every new piece of biological information is useful.

Broad genetic testing can uncover variants of uncertain significance (VUS)– genetic changes whose connection to disease is not yet established. Finding one does not automatically mean that a person has, or will develop, a particular condition. Yet without careful interpretation, uncertain findings can trigger anxiety, unnecessary follow-up testing and sometimes invasive procedures.

This creates what I call the incidentaloma problem of genomics: the ability to detect more abnormalities faster than medicine can confidently explain them.

The same issue can appear outside genetics. More sensitive biomarker testing can identify small biological deviations that may never develop into clinically meaningful disease. If every abnormal result leads to another test, healthcare risks creating a cycle of overdiagnosis rather than prevention.

This is why precision medicine needs a strict principle: information should only be collected when there is a credible pathway from finding it to acting on it.

The goal should not be to know everything about a patient. It should be to know what matters enough to change the outcome. 

The People Problem

Personalized medicine has a technology problem, but it also has a talent problem.

A genomic report can contain thousands of variants, but identifying which ones actually matter requires specialised interpretation. Genetic counsellors, clinical geneticists and physicians trained in genomic medicine are needed to translate complex findings into decisions patients can understand and act on.

The challenge becomes even greater as healthcare moves toward multi-omics– combining genomics with biomarkers, proteomics, metabolomics and continuous health data. More information can improve precision, but it also increases the complexity of interpretation.

AI could help by identifying patterns and reducing the burden of analysing huge datasets. But I do not see AI replacing clinical judgment here. The more complicated the data becomes, the more important human interpretation becomes.

This creates a bottleneck that is easy to overlook. Sequencing can scale much faster than expertise.

Unless healthcare systems invest in the people, training and clinical infrastructure needed to interpret genomic data, personalized medicine risks becoming a technology that can generate remarkable insights but cannot consistently turn those insights into better patient outcomes. 

Conclusion

The biggest mistake would be judging personalized medicine by how much data it can collect. The real test is whether that data leads to better decisions and better outcomes.

Genomics can reveal inherited risk. Biomarkers can show what is changing inside the body. Wearables can add continuous context. AI can help connect these signals. But none of this matters if the information is inaccurate, inaccessible, poorly interpreted or impossible to act on.

That is why I see the next phase of personalized medicine less as a race to collect more data and more as a race to make biological information clinically useful.

The strongest healthcare model will not be the one that predicts the most diseases. It will be the one that knows which risks are meaningful, which interventions are supported by evidence and when doing nothing is actually better than intervening.

If genomic testing becomes affordable, clinical interpretation improves and healthcare systems start rewarding prevention, personalized medicine could fundamentally change the patient journey.

The future of healthcare is not simply knowing more about each person. It is knowing which information matters and acting on it at the right time. 

The post Personalized Medicine and Genomic Health Profiling appeared first on The American Reporter.

Health has become a huge part of their daily lives, content, and decision-making. But as interest has grown, so has the number of tools promising to help people measure it.

For years, health and fitness technology mostly meant tracking steps, calories, workouts, heart rate, or sleep. These tools helped people become more aware of their habits, but now people have more health data than ever and don’t know what to do with it.

While all that data is good, it doesn’t always tell the whole story. Numbers alone don’t always explain what’s happening inside the body or tell someone what’s changing, what needs attention, or how daily habits may be affecting long-term health.

That’s the problem Hume Health is trying to solve.

Led by Co-founders Marius Rønnov (CEO) and Jeff Lee (CMO), Hume Health is building a consumer health technology platform focused on helping people better understand their bodies through AI-driven intelligence, connected psychological data, body composition insights, and personalized guidance. 

Rather than positioning itself as another fitness tracker, Hume Health is creating a connected ecosystem that links measurement, interpretation, and action. Its goal is to help people understand the health markers shaping both lifespan and healthspan: not only how long they live, but how they function and feel through those years.

Why the founders believe health data is changing

The wellness industry has grown rapidly, but much of it has been built around disconnected products. One app tracks sleep, while another tracks workouts. A scale tracks weight, a wearable tracks heart rate, and a lab test may show certain biomarkers. Each tool can be useful, but the average person is often left trying to piece everything together on their own.

Hume Health aims to bring health data into a more connected system by helping users see patterns and understand how different parts of their health may be changing. 

The platform brings behavior tracking, cardiovascular signals, sleep, activity, nutrition, body composition, and, where appropriate, clinical treatment information into one ecosystem. Rather than evaluating every reading separately, Hume interprets how those signals change together and what those changes may mean for the individual’s current health trajectory. 

This approach also looks beyond any single day. One missed workout or poor night of sleep does not define a person’s health. Hume focuses on how patterns develop across weeks and months, comparing recent changes with the user’s own history and broader health context. 

The goal is to build a central platform where health information becomes more useful, more organized, and more connected to everyday decisions. It also reflects growing consumer interest in health aging, metabolic health, body composition, and taking a more active role in long-term wellness.

People are becoming more aware that health isn’t something to think about only when something goes wrong. Many now want to understand their bodies earlier, build better habits sooner, and take a more active role in their long-term well-being.

Hume Health is entering the market at a time when that mindset is becoming more common.

Marius Rønnov’s product vision

Rønnov’s role at Hume Health is deeply tied to the company’s mission. 

Throughout his career, he has focused on building consumer technology products for global platforms — translating complex data into clear, usable insights at scale. At Hume Health, that experience guides the company’s push to make advanced health measurement more practical for the average person. His focus isn’t only on what the platform can measure but on how people experience that information.

Health data can quickly become overwhelming. If people don’t understand what they’re seeing, they may ignore the information completely. Rønnov’s work is focused on making the platform useful, not just impressive.

Under Rønnov’s leadership, Hume Health has grown into a recognized platform in the health technology space, with a particular focus on body composition and metabolic health intelligence designed for at-home use. He is also positioned as a voice in conversations around preventive healthcare, AI-driven health intelligence, longevity, and the future of health measurement outside traditional clinical systems.

For Rønnov, the future of health technology centers around helping individuals better understand their bodies between those moments and giving them information they can use in their daily lives.

Jeff Lee’s growth perspective

If Rønnov is focused on the product and scientific direction, Lee is focused on how to bring that vision to more people.

As Co-founder and CMO, Lee works at the intersection of health technology, human performance, and company building. His role is to help scale Hume Health while making the company’s message clear and approachable.

That background matters because health technology isn’t just a product category. It’s also a trust category. People need to believe that a platform is useful, credible, and relevant to their lives. They need to understand why the information matters and how it can help them make better decisions.

Before Hume Health, Lee built and scaled multiple brands from eight to nine figures. Through that work, he developed experience in growth strategy, customer acquisition, consumer psychology, and scalable marketing infrastructure.

At Hume Health, he applies that experience to a much larger mission.

Lee is a vocal advocate for the future of longevity, preventative healthcare, and human performance. His work is rooted in the belief that lifespan is becoming more measurable, influenceable, and improvable through advances in health data, technology, and behavioral science.

That belief is central to Hume Health’s next phase. The company is trying to help reshape how people think about their long-term health.

Building for lifespan and healthspan

One reason Hume Health’s work feels timely is that more people are becoming familiar with the concept of healthspan. Where lifespan refers to how long a person lives, healthspan refers to how well they live during those years.

People don’t just want to live longer. They want to stay active, strong, independent, and capable for as long as possible. Instead of focusing solely on short-term fitness goals, more people are thinking about muscle preservation, metabolic function, body composition, recovery, and prevention by asking how today’s habits shape tomorrow’s health.

Hume Health is building directly into that interest.

By focusing on body composition and connected health intelligence, the company gives people a way to look beyond weight and begin paying attention to how multiple health markers change together. Two people can weigh the same amount but have very different levels of muscle, fat, hydration, and body composition. A person can also lose weight in a way that doesn’t necessarily support long-term strength or wellness.

Hume Health’s platform is designed to give people a fuller picture, which is also what makes the company’s next phase significant. As Rønnov and Lee continue building Hume Health, they aim to create a more connected way for people to understand their bodies, habits, and long-term health.

For Rønnov, that means continuing to build technology that makes complex health information easier to understand. For Lee, it means bringing that vision to more people in a way that feels clear, useful, and trustworthy.

Together, they are building Hume Health around the belief that the future of health technology will be about more than tracking. It will be about helping people understand what their data means, identify what deserves their attention, and learn which small actions are creating meaningful change over time.

That’s the category Hume Health is trying to define as it enters its next major growth phase.

The post How Two Founders Are Building a Category-Defining Health Intelligence Platform Ahead of a Major Growth Phase appeared first on The American Reporter.

With the peptide therapies trending in the wellness world today, that exchange of information often isn’t happening. Rather, those using peptides for anti-aging and other wellness goals are turning to social media as a key source of peptide education.

“The gold standard for information in any situation involving medical treatment would be specialty board guidance, peer-reviewed clinical literature, FDA labeling for approved indications, and formal continuing medical education delivered through accredited bodies,” says Karthik Achari, Clinician and Founder of PepMD. “That’s how every other therapeutic class gets governed. But peptide medicine doesn’t have most of that.”

Achari founded PepMD in 2026 to address the risks posed by the lack of infrastructure in the rapidly growing field of peptide medicine. Modeled in part after established accreditation systems like The Joint Commission, PepMD credentials clinicians, recognizes pharmacies, and authorizes research sites under a single, unified standard. A clinician by training, Achari attended Bradley University’s Doctor of Nursing Practice Family Nurse Practitioner program and built his perspective on healthcare from direct patient care to operating healthcare businesses. His work focuses on bringing structure, credibility, and oversight to an evolving sector that has outpaced traditional regulatory frameworks.

“With peptide medicine, there’s no specialty board, no widely accepted clinical standards, limited peer-reviewed literature for many of the compounds being prescribed, and no education infrastructure on peptide protocols produced by credentialed institutions,” Achari says. “So the information vacuum gets filled by whoever shows up to fill it, which is increasingly social media.”

Why social media channels are awash with information on peptide therapies

The fact that social media has emerged as a primary source of information for peptide therapies shouldn’t come as a surprise. The same pattern can be seen in other consumer wellness trends, including nutrition, fitness, and mental health.

When the institutional channels that would normally educate the public on a therapeutic category don’t exist or don’t engage, platforms with massive reach and zero credentialing requirements fill the gap. And with peptide medicine, certain factors make it particularly susceptible to this dynamic.

“Peptides happen to be content-friendly,” Achari says. “The mechanisms of cellular signals and receptors lend themselves to short-form explanation, the effects are sometimes visible, and the narrative around performance and longevity translates well to video formats. Commercial incentives are also aligned with content creation, as suppliers, telehealth clinics, and individual practitioners selling peptide services benefit directly from the audience growth that comes from social content. The economic model rewards loud claims and visible personalities, not careful clinical communication.”

Achari also points out that the lack of engagement from traditional gatekeepers has contributed to the flood of information on social media. To date, there’s no peptide-specific specialty board producing content, no major medical association running patient education campaigns, and very limited engagement from academic medicine.

“When the credible institutions don’t show up, the platform doesn’t sit empty,” Achari explains. “It fills with whoever does show up. And patient demand is real, so the gap doesn’t stay unfilled for long.”

How therapeutic peptide users can identify safe information on social media

Social media channels are clearly not a peer-reviewed source for reliable information on peptides. But social media users can still sometimes find credentialed clinicians and academic researchers offering helpful information.

“Some of the content on peptides posted to social media is careful, evidence-grounded, and honest about what’s known versus what isn’t,” Achari says. “The challenge is that the platforms don’t distinguish between content coming from credentialed clinical practices and that produced by people selling products. The algorithm rewards engagement, not accuracy, which means a board-certified endocrinologist’s measured post about GLP-1 doses and monitoring gets the same algorithmic treatment as an influencer’s two-minute video promoting peptides as regenerative medicine.”

Consumers looking for ways to identify reliable information should look carefully at the following factors:

• Credentials: The person posting should be a licensed clinician in a relevant field who has transparently disclosed their credentials, rather than vaguely identifying as a “wellness expert” or “biohacker.”
• Financial relationship: Be wary of those who sell the products they recommend, are affiliated with a clinic that prescribes what they discuss, or are part of an influencer program for a supplier, especially when they don’t disclose that information.
• Handling of uncertainty: Credible voices will acknowledge what isn’t known about the compounds they discuss, citing specific studies, explaining limitations, and providing complete information rather than selective points designed to drive sales. 

Why credentialed clinicians with peptide training should have the final say

Even after filtering information, experts warn that consumers shouldn’t be relying primarily on social media for clinical decisions about peptide medicine. Filtering reduces harm, but doesn’t replace what proper, evidence-based medical literature delivered in the context of a clinical relationship provides for those who want to use peptides safely.

“The peptide medicine information environment gets fixed when institutions and credentialing infrastructure do the work the social media platforms aren’t doing,” Achari says. “If the credible voices don’t show up, the conversation continues with or without them, and patients keep getting their information from the loudest source available.”

The post How Social Media Became the Primary Source for Education on Peptide Therapies appeared first on The American Reporter.

“When you train actors for shirtless scenes or to look good on film, bloating isn’t an option,” Walsh says. “My clients were committed to training hard, which meant increasing protein intake, but every plant protein on the market left them uncomfortable. They were too gritty, had a terrible aftertaste, or triggered uncomfortable digestive issues that killed their confidence.”

When Walsh couldn’t find a protein powder that met his standards, he set out to build one. The result is RISE311, a craft protein formulated to deliver performance without compromise.

“It took 311 iterations to get it right,” Walsh says. “Most brands get to version three and call it done. We got to three hundred and eleven, which is less ‘product development’ and more ‘clinical obsession with a business case.’ RISE311 gets the job done with zero compromises. It has a smooth texture, natural sweetness, and zero digestive issues. No bloating, no grit, and no nasty aftertaste; just optimized performance.”

RISE311 satisfies Jason Walsh’s relentless quest for quality

Walsh is renowned for transforming Hollywood’s elite into the physical powerhouses they need to become to embody the heroes they play on the big screen. His client roster reads like a marquee: Pedro Pascal, Brie Larson, Allison Brie, Bradley Cooper, Jennifer Aniston, Jennifer Lawrence, Matt Damon, and many more. Hollywood stars seek out Walsh because they trust his rigorous, science-backed programs to achieve dramatic physical transformations under tight production timelines.

But Walsh’s mission in the world of fitness extends beyond the red carpet. He is a relentless advocate for quality, known not only for his unmatched training results but also for his integrity in cutting through fitness fads and supplement hype. It was that integrity that fueled the development of RISE311, the first and only craft protein designed to meet the real performance and recovery needs of working professionals, athletes, and anyone serious about results.

“With RISE311, we’ve really crafted the impossible,” Walsh says. “It’s a complete plant-based protein that’s easily digestible, environmentally responsible, and uncompromising on taste, texture, and quality.”

RISE311 is complete nutrition that works

RISE311’s unique ability to deliver performance without compromise stems from the specific formula Walsh and his team developed. By building on pea protein and barley rice protein, RISE311 can deliver the nine essential amino acids the body needs to benefit from training. And by avoiding animal products, RISE311 delivers without digestive issues.

RISE311 earns a perfect 1.0 PDCAAS, the same score as whey. And it delivers 3 grams of leucine per serving, the threshold your body needs to trigger muscle protein synthesis (i.e., grow or maintain muscle). 

“That’s not marketing,” Walsh says. “That’s measurable.”

RISE311 improves fitness results without the nonsense

Just as important as what RISE311 provides is what it avoids. For example, its three-step development process, which includes sprouting its barley protein, fermenting its pea protein, and mixing in a powerful enzyme blend, means RISE311 avoids the digestion issues that cause bloating.

“In addition to making RISE311 easy to digest, our powder’s enzyme blend hydrolyzes the protein in your digestive tract,” Walsh explains. “It’s a process that ensures muscles are flooded with the amino acids they need at the right moment, which puts muscle repair on a fast track.”

Regarding ingredients, RISE311 makes sure its users aren’t exposed to the heavy metals that have been identified as a problem with many protein powders. The brand is manufactured in an NSF GMP-certified facility and is about to complete Informed Sports certification. Ingredients are locally sourced from farms that use high-quality soil to produce high-quality protein, and every batch is lab-tested by a third party for heavy metals and banned substances to ensure the ingredients are safe and pure. 

“RISE311 is fundamentally different from most of the powders on the market because our process starts with choosing the right ingredients,” Walsh shares. “We use best-in-class ingredients and craft in small batches without cutting any corners or taking any shortcuts. Where most protein powder brands optimize for margin, we optimize for what actually goes into your body.”

RISE311’s texture is smooth, meaning there’s no settling, no grit, and no clumps. And because it only uses Reb-M, the sweetness is clean, avoiding the nasty aftertaste found in many powders that use cheap stevias or monk fruit. That’s what you get when a protein powder is formulated for humans, not margins. It mixes clean in water and holds its body in protein shake recipes that go beyond the post-workout shake.

“We chose against organic pea protein on purpose,” says Walsh. “Most organic protein powder is sourced from China, where soil pollution means higher heavy metal levels. Protein powder is processed, so the risk of pesticides making it into the powder is actually very low.”

As Walsh explains, this means that the word “organic” on a protein powder label is more marketing than science. “We source USA-grown pea protein from high-quality soil instead, and every batch tests clean,” he says.

“RISE311 is a protein solution I can stand behind,” Walsh concludes. “It provides 30 grams of protein that digests clean, tastes natural, and delivers results without the compromise. Scoop for scoop, no other protein powder is even close.”

The post Scoop for Scoop, It’s Not Even Close: Why RISE311 Delivers More Protein (and Less Nonsense) appeared first on The American Reporter.